All In Biotech

Drug Trial Radar · NCT05577715

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

31

Actual

Start

Nov 14, 2022

Primary completion

Aug 12, 2024

Study completion Aug 12, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • MORAb-202Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate as Per InvestigatorTime frame: From the date of randomization to the date of first objectively documented progression or death, whichever occurs first (Up to approximately 12 months)
  2. Number of Participants With Drug -Related Adverse Events Leading to DiscontinuationTime frame: From first dose and 30 days after last dose of study therapy (up to approximately 12 months).

Locations

33 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0007

    Orange, California

  • Local Institution - 0035

    Lone Tree, Colorado

  • Local Institution - 0043

    Clermont, Florida

  • Local Institution - 0010

    Orange City, Florida

  • Local Institution - 0001

    Marietta, Georgia

  • Local Institution - 0005

    Louisville, Kentucky

  • Local Institution - 0044

    Silver Spring, Maryland

  • Henry Ford Hospital

    Detroit, Michigan

  • Local Institution - 0002

    Kansas City, Missouri

  • Local Institution - 0011

    Charlotte, North Carolina

  • Local Institution - 0034

    Arlington, Texas

  • Local Institution - 0045

    Flower Mound, Texas

  • Local Institution - 0033

    Fairfax, Virginia

  • Local Institution - 0040

    Wollongong, NS, Australia

  • Local Institution - 0012

    Ballarat Central, Victoria, Australia

  • Local Institution - 0022

    Murdoch, Western Australia, Australia

  • Local Institution - 0036

    Roeselare, Belgium

  • Local Institution - 0039

    Mons, WHT, Belgium

  • Local Institution - 0030

    Independencia, Chile

  • Local Institution - 0027

    Recoleta, Chile

  • Local Institution - 0023

    Santiago, Chile

  • Local Institution - 0028

    Providencia, SA, Chile

  • Local Institution - 0017

    Rouen, France

  • Local Institution - 0015

    Suresnes, France

  • Local Institution - 0014

    Toulon, France

  • Local Institution - 0038

    Villejuif, France

  • Local Institution - 0025

    Barcelona, Spain

  • Local Institution - 0021

    Barcelona, Spain

  • Local Institution - 0018

    Madrid, Spain

  • Local Institution - 0026

    Santiago de Compostela, Spain

  • Local Institution - 0031

    Seville, Spain

  • Local Institution - 0019

    Majadahonda (Madrid), M, Spain

  • Local Institution - 0020

    Málaga, MA, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.